Ruxolitinib clinical trials
Also written Jakafi, INCB018424, Jakavi and INCB18424.
How each study uses ruxolitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ruxolitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Nov 2011 · JAKAFI · NDA 202192 (FDA, Drugs@FDA)
- European Union
- 23 Aug 2012 · Jakavi · EMEA/H/C/002464 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
300 studies that test it; most in 2025 (27); 2 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 7 |
| 2013 | 13 |
| 2014 | 20 |
| 2015 | 13 |
| 2016 | 15 |
| 2017 | 17 |
| 2018 | 18 |
| 2019 | 22 |
| 2020 | 22 |
| 2021 | 14 |
| 2022 | 18 |
| 2023 | 21 |
| 2024 | 22 |
| 2025 | 27 |
| 2026 | 26 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 94 · Other 208
Incyte Corporation (68) · Novartis Pharmaceuticals (21) · M.D. Anderson Cancer Center (15) · Memorial Sloan Kettering Cancer Center (10) · Institute of Hematology & Blood Diseases Hospital, China (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Fred Hutchinson Cancer Center (5) · St. Petersburg State Pavlov Medical University (5)
Often tested with
Tested in the same studies.
Cyclophosphamide (10) · Dexamethasone (7) · Methotrexate (7) · Dasatinib (5) · Tacrolimus (5) · Decitabine (5) · Adrenal Cortex Hormones (4) · Cytarabine (4)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Ruxolitinib is the comparator. A study of two new drugs counts under both.
- 2Bomedemstat · Merck Sharp & Dohme LLC · next primary completion Jul 2027
- 1Flonoltinib · Chengdu Zenitar Biomedical Technology Co., Ltd · next primary completion Dec 2027
Reaching primary completion within a year · 32, 2 in phase 3
Studies that test ruxolitinib, phase 3 first.
- Apr 2027A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoPhase 3 · Incyte Corporation
- Jun 2027Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesPhase 2/3 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Nov 2026Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaPhase 1/2 · Veronika Bachanova
- Nov 2026PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityPhase 2 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Dec 2026Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLPhase 2 · Massachusetts General Hospital
- Dec 2026Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized VitiligoNot applicable · Kafrelsheikh University
- Dec 2026Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaPhase 1 · Incyte Corporation
- Dec 2026Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorPhase 2 · St. Petersburg State Pavlov Medical University
- Dec 2026A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmPhase 1 · AbbVie
- Jan 2027A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisPhase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses ruxolitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 302
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02974647Written as Ruxolitinib
- Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)Not yet recruitingPhase 1Children's Hospital Medical Center, CincinnatiNCT07801248Written as Ruxolitinib 1.5% cream
- A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host DiseaseRecruitingPhase 2M.D. Anderson Cancer CenterNCT06973668Written as Ruxolitinib
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingPhase 1City of Hope Medical CenterNCT07278856Written as Ruxolitinib Phosphate
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05398809Written as Ruxolitinib
- A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07913672Written as Ruxolitinib
- Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized VitiligoEnrolling by invitationNot applicableKafrelsheikh UniversityNCT07909668Written as Ruxolitinib 1.5% cream
- Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingPhase 1/2Veronika BachanovaNCT03681561Written as Ruxolitinib
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07311746Written as Ruxolitinib
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingPhase 2Ohio State University Comprehensive Cancer CenterNCT07356245Written as Ruxolitinib
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraRecruitingPhase 3University of BirminghamNCT04116502Written as Ruxolitinib
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingPhase 3Incyte CorporationNCT06615050Written as Ruxolitinib (Rux)
- daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07588945Written as Ruxolitinib
- Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingPhase 2University Hospital, Basel, SwitzerlandNCT07840456Written as Ruxolitinib
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingPhase 2/3Bambino Gesù Hospital and Research InstituteNCT07297914Written as Ruxolitinib
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07228624Written as Ruxolitinib
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruitingPhase 1University of UtahNCT07521046Written as Ruxolitinib
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingPhase 2City of Hope Medical CenterNCT06128070Written as Ruxolitinib Phosphate
- Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingEarly Phase 1Baylor Research InstituteNCT06008275Written as Ruxolitinib Oral Tablet
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoRecruitingPhase 3Incyte CorporationNCT06804811Written as Ruxolitinib Cream
See all 302 studies that test ruxolitinib →
Given beside what is tested · 68 — ruxolitinib is usual care or a partner of the new treatment
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)RecruitingPhase 3Novartis PharmaceuticalsNCT07357727Written as Ruxolitinib
- An Extension Study for Patients Previously Enrolled in Studies With PelabresibRecruitingPhase 3Novartis PharmaceuticalsNCT06401356Written as Ruxolitinib
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsRecruitingPhase 1Janssen Research & Development, LLCNCT06150157Written as Ruxolitinib
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)RecruitingPhase 1/2Michael SavonaNCT04061421Written as Ruxolitinib
- A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsRecruitingPhase 1Damora TherapeuticsNCT07849231Written as Ruxolitinib
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Ruxolitinib
- A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingPhase 1/2Sumitomo Pharma America, Inc.NCT04176198Written as Ruxolitinib
- Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host DiseaseRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT04744116Written as Ruxolitinib
- RVU120 Rollover StudyEnrolling by invitationPhase 2Ryvu Therapeutics SANCT06987058Written as Ruxolitinib
- Revumenib in Patients With MyelofibrosisNot yet recruitingPhase 1/2John MascarenhasNCT07734077Written as Ruxolitinib
- CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Stephan Grupp MD PhDNCT07464951Written as Ruxolitinib (JAKAVI®)
- Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDRecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT07184853Written as Ruxolitinib (JAKAVI®)
- Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHDNot yet recruitingPhase 4Peking University People's HospitalNCT06364319Written as Ruxolitinib
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingPhase 1Mayo ClinicNCT03017820Written as Ruxolitinib
- Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06327100Written as Ruxolitinib
- A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid TumorsNot yet recruitingPhase 1Philogen S.p.A.NCT07566897Written as Ruxolitinib
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingPhase 1Incyte CorporationNCT06034002Written as Ruxolitinib
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingPhase 2Karyopharm Therapeutics IncNCT05980806Written as Ruxolitinib
- A Study of Elritercept Alone or Together With Ruxolitinib in Adults With MyelofibrosisRecruitingPhase 2TakedaNCT05037760Written as Ruxolitinib
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibRecruitingPhase 3Kartos Therapeutics, Inc.NCT06479135Written as Ruxolitinib
Showing 20 of 68.
As the comparator · 12 — what is tested is compared with ruxolitinib
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07722611Written as Ruxolitinib
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisRecruitingPhase 3Chengdu Zenitar Biomedical Technology Co., LtdNCT07317700Written as Ruxolitinib Phosphate
- BeFluBu vs FluBuRux Conditioning in Haploidentical HCTRecruitingPhase 2St. Petersburg State Pavlov Medical UniversityNCT06477549Written as Ruxolitinib
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as Ruxolitinib
- A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk MyelofibrosisActive, not recruitingPhase 2Chengdu Zenitar Biomedical Technology Co., LtdNCT06457425Written as Ruxolitinib
- A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic DermatitisCompletedPhase 2CAGE Bio Inc.NCT06923228Written as Ruxolitinib 1.5% Cream QD
- Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor AvailabilityActive, not recruitingPhase 2Universitätsklinikum Hamburg-EppendorfNCT03333187Written as Ruxolitinib continuous therapy
- A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.CompletedPhase 1Taro Pharmaceuticals USANCT06673654Written as OPZELURA (Ruxolitinib) Cream
- A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)TerminatedPhase 3XenikosNCT04934670Written as Ruxolitinib
- Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedPhase 3Sierra Oncology LLC - a GSK companyNCT01969838Written as Ruxolitinib
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraStatus unknownPhase 2Kartos Therapeutics, Inc.NCT03669965Written as Ruxolitinib
- Open-Label Crossover Study Comparing CTP-543 to Jakafi®CompletedPhase 1Concert PharmaceuticalsNCT02960945Written as Jakafi 15Mg Tablet
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLOct 20, 2026NCT07297914
Results posted1
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeNov 12, 2026NCT00044304
Newly registered2
- A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)Nov 3, 2026NCT07913672
- Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized VitiligoNov 2, 2026NCT07909668
Codes
What other systems call ruxolitinib · ClinicalTrials.gg INT005425
- MeSH (NLM) C540383ruxolitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 82S8X8XX8HRUXOLITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1193326Confirmed FDA, Wikidata
- Wikidata Q7383611ruxolitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77888RuxolitinibOne source FDA
- DrugBank DB08877One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C540383 | ruxolitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 82S8X8XX8H | RUXOLITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1193326 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7383611 | ruxolitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77888 | Ruxolitinib | One source FDA |
| DrugBank | DB08877 | — | One source Wikidata |
Also registered as ruxolitinib phosphate (UNII 436LRU32H5 · RxNorm 1193325).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.